Induced Pluripotent Stem Cells Market Insights on Trends, Application, Types and Users Analysis 2019-2025 – News Times

TMRR in its latest research report states that the global market size of Induced Pluripotent Stem Cells market was $XX million in 2018 with XX CAGR from 2014 to 2018, and is expected to reach $XX million by the end of 2029 with a CAGR of XX% from 2019 to 2029.

Global Induced Pluripotent Stem Cells Market Report 2019 Market Size, Share, Price, Trend and Forecast is an intuitive and exhaustive study on the current and future prospects of the global Induced Pluripotent Stem Cells industry. The key insights are elucidated as under:

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6245&source=atm

There are 4 key segments covered in this report: machine segment, product type segment, end use segment and regional segment.

Competitive landscape of Induced Pluripotent Stem Cells market has tier 1, tier 2 and tier 3 players and provides a dashboard view of their strategies and intensity mapping.

Notable Development

Over the past few years, fast emerging markets in the global induced pluripotent stem cells are seeing the advent of patents that unveil new techniques for reprogramming of adult cells to reach embryonic stage. Particularly, the idea that these pluripotent stem cells can be made to form any cells in the body has galvanized companies to test their potential in human cell lines. Also, a few biotech companies have intensified their research efforts to improve the safety of and reduce the risk of genetic aberrations in their approved human cell lines. Recently, this has seen the form of collaborative efforts among them.

Lineage Cell Therapeutics and AgeX Therapeutics have in December 2019 announced that they have applied for a patent for a new method for generating iPSCs. These are based on NIH-approved human cell lines, and have been undergoing clinical-stage programs in the treatment of dry macular degeneration and spinal cord injuries. The companies claim to include multiple techniques for reprogramming of animal somatic cells.

Such initiatives by biotech companies are expected to impart a solid push to the evolution of the induced pluripotent stem cells.

North America is one of the regions attracting colossal research funding and industry investments in induced pluripotent stem cells technologies. Continuous efforts of players to generate immune-matched supply of pluripotent cells to be used in disease modelling has been a key accelerator for growth. Meanwhile, Asia Pacific has also been showing a promising potential in the expansion of the prospects of the market. The rising number of programs for expanding stem cell-based therapy is opening new avenues in the market.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=6245&source=atm

For regional segment, the following regions in the Induced Pluripotent Stem Cells market have been covered

Reasons to Purchase this Report:

We also can offer customized report to fulfil special requirements of our clients. Regional and Countries report can be provided as well.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6245&source=atm

More:
Induced Pluripotent Stem Cells Market Insights on Trends, Application, Types and Users Analysis 2019-2025 - News Times

Bit Bio Secures Distribution Agreement with Abcam to Democratize Access to Human Cells for Global Life Science Research – BioSpace

CAMBRIDGE, England, Feb. 25, 2020 /PRNewswire/ --Bit Bio announces agreement with Abcam, a global innovator in life science reagents and tools, to make Bit Bio's iPSC derived functional human cells widely available to the global life science community. Over the course of the next two years this new partnership will provide an increasing range of highly defined, scalable and consistent human cells for research and high-throughput screening applications. The first product available are brain cells (ioNEURONS/glutTM, glutamatergic neurons) serving the neuroscience community.

Access to human cells is a significant bottleneck in the field of medical research and drug development. Human cells differ from animal models, and therefore research using animal models often does not translate into clinical applications.

Bit Bio is commercializing opti-oxTM, a precise reprogramming proprietary technology platform that enables uniquely efficient and consistent production of human cells for use in research, drug discovery, and cell therapy.

"Bit Bio's goal is to develop a scalable technology platform capable of producing consistent batches of every human cell type," said Bit Bio CEO Mark Kotter, a neurosurgeon at Cambridge University, and stem cell biologist. "This agreement will accelerate our mission of putting highly defined human cells in the hands of the researchers who need them to pursue their life-saving work."

"Supporting enhanced access to complementary technologies that have the potential to improve and accelerate research is part of our growth strategy," said John Baker, Senior Vice President Product Portfolio and Innovation at Abcam. "Our industry expertise, and co-location in major biotechnology hubs throughout the world, enables our partners to rapidly put their innovations into the hands of the global research community, helping advance the understanding of biology and cause of disease to enable new treatments and improved health outcomes."

Bit Bio's breakthrough technology has been successfully employed to reprogram stem cells into functional neurons on a scalable and consistent basis. The proprietary approach ensures batch to batch reproducibility and unprecedented purity compared to current technologies and yields fully differentiated neurons within days. The protocol is also universally applicable, from small-scale laboratory research projects to high throughput screens in pharmaceutical R&D laboratories.

Bit Bio's human-induced glutamatergic neurons are a highly defined and consistent human model for the study of neurological physiology and disease, including neurodegeneration, and are available from the Abcam website.

"At Bit Bio we believe that world-wide access to our iPSC derived cells will drive human translational experiments and ultimately help to fuel the next generation of medicine," said Bit Bio Chief Business Officer Paul Morrill. "Abcam's reputation as a disruptive innovator in the field of biological reagents and dedicated global commercialization infrastructure make them the ideal partner. In line with our core value of democratizing access to human cells for research and drug development, our ioNEURONS/glut are offered at a highly competitive price point."

About Bit Bio

Bit Bio, the cell coding company, is based in Cambridge, UK. Bit Bio's team includes world leaders in stem cell biology, cellular reprogramming and cell therapy who are harnessing the power of synthetic biology to tackle the problem of inconsistency in the production of human cells. Bit Bio is developing opti-oxTM, a proprietary technology platform capable of producing any human cell for research, drug discovery and cell therapy.

We areintroducing ioNEURONS/glutTM,human-induced glutamatergic neuronscells, providing a high-quality human model for research, drug development and high-throughput screening.ioNEURONS/glut cells have been reprogrammed from human induced pluripotent stem cells (hiPSC) using a precise reprogramming technology.

To find out more, please visit http://www.bit.bio

Bit Bio press contact:Dr Farah Patell-Socha, press@bit.bio

About AbcamAs a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Abcam partners with life science organisations to co-create novel binders for use in drug discovery,in vitrodiagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading, antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products. With eleven sites globally, many of Abcam's 1,100 strong team are located in the world's leading life science research hubs, complementing a global network of services and support.

To find out more, please visitwww.abcam.comandwww.abcamplc.com.

Abcam press contact:Dr Lynne Trowbridge, lynne.trowbridge@abcam.com

View original content:http://www.prnewswire.com/news-releases/bit-bio-secures-distribution-agreement-with-abcam-to-democratize-access-to-human-cells-for-global-life-science-research-301010337.html

SOURCE Bit Bio

View original post here:
Bit Bio Secures Distribution Agreement with Abcam to Democratize Access to Human Cells for Global Life Science Research - BioSpace

Stem Cell and Regenerative Therapy Market To Witness High Exponential Growth By 2020 2026 – Galus Australis

This Stem Cell and Regenerative Therapy Market research report is focused at providing its reader with all the necessary details that can help them make necessary business decisions. It provides wholesome information that is necessary to understand the market inside-out.

ReportsnReports has recently added a new research report to its expanding repository. The research report, titled Stem Cell and Regenerative Therapy Market, mainly includes a detailed segmentation of this sector, which is expected to generate massive returns by the end of the forecast period, thus showing an appreciable rate of growth over the coming years on an annual basis. The research study also looks specifically at the need for Stem Cell and Regenerative Therapy Market.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Download A Sample Report athttps://www.reportsnreports.com/contacts/requestsample.aspx?name=2351731

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Please Share Your Specific Interest To Serve You Better | Download PDF Brochure athttps://www.reportsnreports.com/contacts/requestsample.aspx?name=2351731

Summary:

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Access Full Report athttps://www.reportsnreports.com/purchase.aspx?name=2351731

Recent Industry Trend:

The report contains the profiles of various prominent players in the Global Stem Cell and Regenerative Therapy Market. Different strategies implemented by these vendors have been analyzed and studied in order to gain a competitive edge, create unique product portfolios and increase their market share. The study also sheds light on major global industry vendors. Such essential vendors consist of both new and well-known players. In addition, the business report contains important data relating to the launch of new products on the market, specific licenses, domestic scenarios and the strategies of the organization implemented on the market.

Scope of the Report:

Through following the Stem Cell and Regenerative Therapy Market through depth, the readers should find this study very helpful. The aspects and details are depicted by charts, bar graphs, pie diagrams, and other visual representations in theStem Cell and Regenerative Therapy Market study. This intensifies the representation of the pictures and also helps to improve the facts of the Stem Cell and Regenerative Therapy Market industry. At a substantial CAGR, the Stem Cell and Regenerative Therapy Market is likely to grow. Stem Cell and Regenerative Therapy Market reports main objective is to guide the user to understand the market in terms of its definition, classification, industry potential, the latest trends, and the challenges facing the Stem Cell and Regenerative Therapy Market.

And More

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.We provide 24/7 online and offline support to our customers.

E-mail: sales@reportsandreports.com

Phone: +1 888 391 5441

Originally posted here:
Stem Cell and Regenerative Therapy Market To Witness High Exponential Growth By 2020 2026 - Galus Australis

Hematopoietic Stem Cell Transplantation (HSCT) Market Trend Forecast And Growth Drivers by 2026 – News Parents

The Hematopoietic Stem Cell Transplantation (HSCT) Market is a broad research dependent on industry, which examines the escalated structure of the present market all around the world. Planned by the sufficient orderly system, for example, SWOT investigation, the Hematopoietic Stem Cell Transplantation (HSCT) market report demonstrates an aggregate appraisal of overall business overview.

Get Free PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1250

Hematopoietic Stem Cell Transplantation (HSCT) Marketreport would come in handy to understand your competitors and give you an insight into sales, volumes, revenues in the Hematopoietic Stem Cell Transplantation (HSCT) industry, assists in making strategic decisions. The report contains proven analysis by regions.It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the market.

The global Hematopoietic Stem Cell Transplantation (HSCT) market research include the decisive analysis by classifying it on the basis of product type, end-user, and application segments. The development of every segment is assessed along with the forecast of their expansion in the near future. The pertinent facts and figures gathered from the regulatory authorities are presented in the global Hematopoietic Stem Cell Transplantation (HSCT) research report to review the expansion of each segment.

Furthermore, the market is bifurcated on the basis of geographical regions such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Numerous analytical techniques are used to study the expansion of the global Hematopoietic Stem Cell Transplantation (HSCT) market. It also highlights key parameters of the dominating market players influencing the growth of the industry along with their position in the global market.

Report Highlights:

Hematopoietic Stem Cell Transplantation (HSCT) Market Drivers & Challenges

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Answers the following Key Questions.

Get Free Request Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1250

Reasons for Buying Hematopoietic Stem Cell Transplantation (HSCT) market

Thus, the report extends from market scenarios to comparative pricing between major players, cost and profit of the specified market regions. The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, PESTLE analysis and so on. The statistics are represented in graphical format for a clear understanding of facts and figures.

About us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:[emailprotected]

U.S. Office:Name: Mr. ShahCoherent Market Insights1001 4th Ave,#3200 Seattle, WA 98154, U.S.US : +1-206-701-6702UK : +44-020-8133-4027JAPAN : +050-5539-1737

Visit link:
Hematopoietic Stem Cell Transplantation (HSCT) Market Trend Forecast And Growth Drivers by 2026 - News Parents

The personal and professional collide in a scientist’s story of early human development – Science Magazine

Magdalena Zernicka-Goetz and Roger HighfieldBasic Books2020304 pp.Purchase this item now

With one phone call, Magdalena Zernicka-Goetzs life as a scientist collided with her personal life in the most dramatic way. As Zernicka-Goetz stood at her desk at the University of Cambridge, a genetic counselor explained that some cells derived from the placenta supporting her fetus carried a serious chromosomal anomaly. But her knowledge of how embryos develop suggested that the fetus might be able to exclude the cells with the genetic abnormality or that it may not contain the damaged DNA at all. Further testing confirmed that the fetus was genetically normal, and her son was born in perfect health. At the time, however, she writes, I couldnt possibly be sure.

In The Dance of Life, Zernicka-Goetz and science writer Roger Highfield weave Zernicka-Goetzs personal memoir together with an accessible introduction to contemporary mouse and human embryonic research and with a discussion of the clinical, ethical, and societal implications of this research and related areas. This is a lofty goal for a relatively slim volume, and it succeeds better in some parts than in others.

Developmental biologists have studied the progression of the fertilized mammalian egg through its early cleavage divisions to the formation of the 100-cell blastocyst for many years. Such studies have suggested that there is a gradual segregation of cell fate influenced by cell polarity, cell position (inside or outside), and mechanical signals and that the embryo is able to regulate for loss, gain, or rearrangement of cells right up to the blastocyst stage. However, none of these studies really addressed the question of whether there might be asymmetries in the egg or early embryo that could bias later cell fate.

Zernicka-Goetz, who has long been fascinated with patterning in the early embryo, took on this challenge when she began her own research lab at the University of Cambridge. She describes her work on defining early asymmetries in the mouse embryo and their role in informing later development in careful detail, recounting how she used tools such as cell marking, live imaging, and gene manipulation to determine that early blastomeres show a bias toward different regions and cell types of the blastocyst. However, other researchersusing different techniquesfound less evidence for early differences, leading to some vigorous debates, as described in the book.

This controversy compelled researchers who had set aside work on the early embryo to reenter the fray, bringing new tools and ideas. And, although it is still not clear what initiates asymmetries after fertilization, it is increasingly clear that by the four-cell stage, there are differences in chromatin modification and transcription factor activity among the cells that, while not permanently specifying cell fate, may bias their future lineage contributions.

The book does not shy away from discussing the moral and ethical implications inherent in such research, tackling prenatal testing, the ongoing quest to create synthetic embryos, and the question of whether human embryos should be used in research. Although an early embryo is not a person, I believe that it deserves protection, and I fully appreciate that balancing that protection with scientific research is not easy, writes Zernicka-Goetz of the latter issue. Her attitude has been to tread carefully, weighing potential concerns against potential value to humanity. I believe in taking a measured approach to enable research that is fully consistent with our values.

The authors do their best to describe experiments on the early embryo and stem cellbased embryo models in simple terms, but the book would have been greatly enhanced by the inclusion of some illustrations. The early embryo is truly beautiful, especially when the complexity of gene expression patterns is revealed by fluorescent imaging. Also, some of the science may be hard for the uninitiated to follow. In the fifth chapter, for example, the embryonic cleavage divisions from one cell to four cells are described using a two-tone soccer ball analogy. This takes two full paragraphs to explain a concept that could have been easily conveyed with a simple diagram.

The most engaging parts of The Dance of Life are the personal stories about the trials and tribulations Zernicka-Goetz has faced during her life in science. Scientific disagreements occur, papers get rejected, grants are not funded, and balancing family and work is never easy. Those of us who, like Zernicka-Goetz, are developmental biologists are in the fortunate position of being in a field where many leading scientists are women (no all-male panels for us!), but female scientists still struggle to overcome the persistent biases and societal and institutional barriers that block their progress. At the end of the day howeveras Zernicka-Goetz and Highfield so ably showthe thrill of scientific discovery is what keeps us coming back to the bench.

The reviewer is president and scientific director of the Gairdner Foundation, Toronto, ON M5G 1L7, Canada, and a senior scientist at the Hospital for Sick Children, University of Toronto, Toronto, ON M5G 0A4, Canada.

More:
The personal and professional collide in a scientist's story of early human development - Science Magazine

Global Cancer Stem Cell Therapy Market 2020: What Are The Key Trends In Market? – Chronicles 99

The latest version of the 2020 market study on Cancer Stem Cell Therapy Market comprising 97 with market data Tables, Charts, Graphs, and Figures which are easy to understand with showcased in-depth analysis.

The global Cancer Stem Cell Therapy market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Cancer Stem Cell Therapy by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Check out sample report at: https://www.amplemarketreports.com/sample-request/global-cancer-stem-cell-therapy-market-1351346.html

As per the research and study, the market has settled its presence worldwide. Cancer Stem Cell Therapy Market Research study offers a comprehensive evaluation of the Market and comprises a future trend, current growth factors, focused opinions, details, and industry certified market data.

Glancing to 2020, the global market expected to be a significant year for Cancer Stem Cell Therapy Market in terms of growth and revenue.

Almost all companies who are listed or profiled are being to upgrade their applications for end-user experience and setting up their permanent base in 2020. This report focused and concentrate on these companies including AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

Furthermore, the research contributes an in-depth overview of regional level break-up categorized as likely leading growth rate territory, countries with the highest market share in past and current scenario. Some of the geographical break-up incorporated in the study are AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

With the Cancer Stem Cell Therapy market forecast to expand CAGR% in 2020 and with X-X-X-X supposed to be a big beneficiary, it is better positioned than Z-Z-Z-Z for 2020.

According to the AMR market study, Recent trends in consumer preferences market segments such as type, application will be more challenging. Cancer Stem Cell Therapy market segment sales will traverse the $$ mark in 2020.

Unlike classified segments successful in the industry such as by Type (Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Others) and by End-Users/Application (Hospital, Clinic, Medical Research Institution, Others).

The 2020 version of the Cancer Stem Cell Therapy market study is a further split down / narrowed to highlight the latest emerging twist of the industry.

Enquire more before buy at: https://www.amplemarketreports.com/enquiry-before-buy/global-cancer-stem-cell-therapy-market-1351346.html

Due to a change in consumer preferences with a review on the latest sales and revenue report submissions, Major vendors in the Global market are trying to get the attention of end-users or consumers by Offerings and additional services.

With using the latest technology and analysis on demand-side, Key players are getting in consumer behavior and their changing preferences.

Again, big investment firms or giants are willing to put more capital to get a key players performance in the market for new applications or products.

Discount, Know more this research report at: https://www.amplemarketreports.com/discount-request/global-cancer-stem-cell-therapy-market-1351346.html

Research Objectives and Purpose

Read More about this report at: https://www.amplemarketreports.com/report/global-cancer-stem-cell-therapy-market-1351346.html

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Western / Eastern Europe or Southeast Asia.

With the given market data, Research on Global Markets offers customizations according to specific needs. Write to AMR at sales@amplemarketreports.com, or connect via +1-530-868-6979

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

https://www.amplemarketreports.com

Read more:
Global Cancer Stem Cell Therapy Market 2020: What Are The Key Trends In Market? - Chronicles 99

Longevity and Anti-senescence Therapy Market Analysis, Segmentation, Key Players, Opportunities and Forecast 2020 2026 – Galus Australis

This Longevity and Anti-senescence Therapy Market research report is focused at providing its reader with all the necessary details that can help them make necessary business decisions. It provides wholesome information that is necessary to understand the market inside-out.

ReportsnReports has recently added a new research report to its expanding repository. The research report, titled Longevity and Anti-senescence Therapy Market, mainly includes a detailed segmentation of this sector, which is expected to generate massive returns by the end of the forecast period, thus showing an appreciable rate of growth over the coming years on an annual basis. The research study also looks specifically at the need for Longevity and Anti-senescence Therapy Market.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which include stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Download A Sample Report athttps://www.reportsnreports.com/contacts/requestsample.aspx?name=2255402

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary:

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and the anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Please Share Your Specific Interest To Serve You Better | Download PDF Brochure athttps://www.reportsnreports.com/contacts/requestsample.aspx?name=2255402

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

Recent Industry Trend:

The report contains the profiles of various prominent players in the Global Longevity and Anti-senescence Therapy Market. Different strategies implemented by these vendors have been analyzed and studied in order to gain a competitive edge, create unique product portfolios and increase their market share. The study also sheds light on major global industry vendors. Such essential vendors consist of both new and well-known players. In addition, the business report contains important data relating to the launch of new products on the market, specific licenses, domestic scenarios and the strategies of the organization implemented on the market.

Access Full Report athttps://www.reportsnreports.com/purchase.aspx?name=2255402

Scope of the Report:

Through following the Longevity and Anti-senescence Therapy Market through depth, the readers should find this study very helpful. The aspects and details are depicted by charts, bar graphs, pie diagrams, and other visual representations in the longevity and Anti-senescence Therapy Market study. This intensifies the representation of the pictures and also helps to improve the facts of the Longevity and Anti-senescence Therapy Market industry. At a substantial CAGR, the Longevity and Anti-senescence Therapy Market is likely to grow. Longevity and Anti-senescence Therapy Market reports main objective is to guide the user to understand the market in terms of its definition, classification, industry potential, the latest trends, and the challenges facing the Longevity and Anti-senescence Therapy Market.

And More

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.We provide 24/7 online and offline support to our customers.

E-mail: sales@reportsandreports.com

Phone: +1 888 391 5441

See the original post:
Longevity and Anti-senescence Therapy Market Analysis, Segmentation, Key Players, Opportunities and Forecast 2020 2026 - Galus Australis

Searching for the ‘big break’ that could turn stem cells into a weapon against dementia – Genetic Literacy Project

Recent developments in the field of stem cell research are paving a path towards a radical shift in the way we diagnose and treat dementia. Stem cells have excited scientists for years and research groups across the globe are using them to advance modern medicine. Using stem cells to aid the fight against dementia is perhaps one of the most critical applications of the technology. Dementia is the leading cause of death in the UK, sixth in US and fifth globally, with an estimated 50 million people currently affected.

The term dementia does not relate to a single disease, but more an array of symptoms that can arise from multiple conditions. The most common is Alzheimers disease (AD) which accounts for up to 80% of all cases. Dementia itself is caused by the death of cells that make up the complex circuitry of our brains and an eventual loss of large portions of the brain. Patients suffering with dementia often exhibit the same general symptoms such as confusion, memory loss and an inability to perform day to day functions. It is a debilitating condition that often strikes the most vulnerable members of society and, consequently, many research groups around the globe work to try to understand dementia-causing diseases to provide better diagnostic and treatment platforms.

In 2007, a research group at Kyoto University in Japan published a study with the potential to change the face of research into dementia along with many other fields. Professor Shinya Yamanaka and his research team developed a method whereby stem cells (cells that can be transformed/differentiated into cells from any tissue) could be generated from a sample of skin. The study, which resulted in a 2012 Nobel Prize for Prof. Yamanaka, demonstrated that skin cells could be isolated from a patient and genetically reprogrammed into induced pluripotent stem cells (iPSCs). In short, this technology made it possible to generate and study brain cells from a patient with dementia without having to remove any of their brain. All they would need to do is provide scientists with a sample of skin.

Since this development, research groups around the globe have started using iPSCs from many patients with dementia in order to understand the biological mechanisms that underlie disease. Dr Eric Hill runs a research group at Aston University in the UK that specializes in iPSCs for dementia research and he had the following to say about the technology:

Its really exciting because it allows us to study cells with genetic mutations that are patient specific. We can get a much better picture of what is actually happening in the brains of these patients. We can now generate all the different cell types found in the human brain and understand how they function together and map the changes that result in disease.

The latter was perhaps most powerfully demonstrated in a study published by a team at the University of North Carolina, led by Professor Hansang Cho. The team was able to generate three key cell subtypes that play important roles in brain function; study the impact of mutations associated with Alzheimers disease; and even replicate some of the core malfunctions found to trigger disease in the brains of patients.

Studies like this are of significance because a large part of the focus in dementia research is on trying to understand how such changes in function arise. When a patient is diagnosed with a disease such as Alzheimers it is often too late for effective treatment. Scientists, instead, seek to elucidate those early changes in brain cell function in order to diagnose patients earlier to give more time for treatment. It is very much a case of prevention being better than a cure. Dr Hill provided an encouraging statement regarding this:

When we generate brain cells from iPSCs the cells we get are developmentally very young. What is interesting is the fact we still see differences between cells from dementia patients versus healthy patients suggesting we could find markers to help us detect and prevent disease some years before it develops.

Despite such promise, however, iPSCs have yet to provide the field of dementia research with that big break. Multiple treatments have progressed into clinical trials since the technology first emerged but no therapies have been approved. Drugs that show promise in the lab fail to deliver on their potential in patient clinical trials, sending researchers back to square one.

We should not be disheartened by this, however, and should instead view it as space into which the technology of using iPSCs to study dementia can grow. A lot of drugs fail in clinical trials because the platforms used to run initial tests dont provide scientists with a wide enough perspective of how those drugs will influence human cells. Additionally, many preclinical studies use animals with dementia-causing disease artificially induced into them. Studies like this often fail to translate into humans because the initial data is not from a human perspective. This is where researchers like Dr. Hill think iPSCs can provide us with an advantage:

iPSCs could provide us with much better platforms for screening drugs to treat and prevent these diseases. They can really add to what we already have, and while we might not be able to grow a full human brain, we can generate the cells that provide the building blocks for one. They give us the chance to screen new therapies more efficiently, better test their effectiveness and reduce the amount of animal use in dementia research.

Dr Hill is not alone in seeing the promise of using iPSCs to find better treatments for preventing the progression of dementia. Multiple research groups around the world have shown the potential of iPSC-derived brain cells for studying the effectiveness of new therapies.

In the last 12 months we have observed a wave of new studies using iPSCs to try to develop better treatments for diseases like Alzheimers, Parkinsons, Huntingtons disease and ALS. From studies in the University of California identifying cholesterol metabolism as a potential target to treating Alzheimers to studies in Luxembourg helping us find better treatments for Parkinsons, it is easy to see why the global effort to get that big break from iPSCs continues to gain interest. We might still be waiting for that next Noble Prize-winning discovery that will improve the lives of millions of patients but the collective effort of iPSC research groups across the world brings us a step closer with every study they publish. Dementia may, one day, be a thing of the past and iPSC research will likely be a significant part in getting us there.

Sam Moxon has a PhD in regenerative medicine and is currently involved in dementia research. He is a freelance writer with an interest in the development of new technologies to diagnose and treat degenerative diseases. Follow him on Twitter @DrSamMoxon

Link:
Searching for the 'big break' that could turn stem cells into a weapon against dementia - Genetic Literacy Project

Radiation, Inflammation and Triple-Negative Breast Cancer: A Study – OncoZine

Although radiation is successfully used to treat breast cancer, inflammation caused as a side-effect of radiation may have an adverse effect, promoting the survival of triple-negative breast cancer cells.

This is the conclusion of a study by Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCares Helen F. Graham Cancer Center & Research Institute, published online in the International Journal of Radiation Biology.[1]

Triple-negative breast cancer is cancer that tests negative for estrogen receptors, progesterone receptors, and excess human epidermal growth factor receptor 2 (HER2) protein. As a result, the growth of this cancer is not fueled by the hormones estrogen and progesterone, or by the HER2 protein. These cancers tend to be more common in women under age 40, who are African-American, Latina, or who carry a mutated BRCA1 gene.

Triple-negative breast cancer accounts for 15-20% of all breast cancers and is faster growing than other types of breast cancers.

Sims-Mourtadas latest study helps scientists to better understand the mechanisms behind the development of this aggressive and hard-to-treat cancer. It shows that inflammation caused by radiation can trigger stem-cell-like characteristics in non-stem breast cancer cells.[1]

The good and the badThis is the good and the bad of radiation, Sims-Mourtada noted. We know radiation-induced inflammation can help the immune system to kill tumor cells thats good but also it can protect cancer stem cells in some cases, and thats bad.

Whats exciting about these findings is were learning more and more that the environment the tumor is in its microenvironment is very important. Historically, research has focused on the genetic defects in the tumor cells. Were now also looking at the larger microenvironment and its contribution to cancer, she added.

My work focuses on cancer stem cells and their origination. [These cells] exist in many cancers, but theyre particularly elusive in triple-negative breast cancer. Their abnormal growth capacity and survival mechanisms make them resistant to radiation and chemotherapy and help drive tumor growth, Sims-Mourtada explained.

The researchers applied radiation to triple-negative breast cancer stem cells and to non-stem cells. In both cases, they found radiation-induced an inflammatory response that activated the Il-6/Stat3 pathway, which plays a significant role in the growth and survival of cancer stem cells in triple-negative breast cancers. They also found that inhibiting STAT3 blocks the creation of cancer stem cells. As yet unclear is the role IL-6/STAT3 plays in transforming a non-stem cell to a stem-cell.

DelawareFor women living in Delaware, Sims-Mourtadas research is especially urgent: The rates of triple-negative breast cancer in the state are the highest nationwide.

At ChristianaCare, we are advancing cancer research to help people in our community today, while we also advance the fight against cancer nationwide, said Nicholas J. Petrelli, M.D., Bank of America endowed medical director of the Helen F. Graham Cancer Center & Research Institute.

Sims-Mourtadas research is a dramatic step toward better treatments for triple-negative breast cancer, Petrelli concluded.

To advance her research on inflammation, last year Sims-Mourtada received a US $ 659,538 grant from the Lisa Dean Moseley Foundation. The three-year grant will enable her and her team at the Cawley Center for Translational Cancer Research to continue investigating the role of cells immediately around a tumor in spurring the growth of triple-negative breast cancer and possible therapy for this particularly difficult to treat cancer.

Our next step is to understand the inflammatory response and how we might inhibit it to keep new cancer stem cells from developing, Sims-Mourtada said.

The researchers previously identified an anti-inflammatory drug, currently used to treat rheumatoid arthritis, that has the potential to target and inhibit the growth of cancer stem cells and triple-negative breast cancer tumors. That research could set the stage for clinical investigation of the drug, alone or in combination with chemotherapy, to improve outcomes for patients with triple-negative breast cancer.

Reference[1] Arnold KM, Opdenaker LM, Flynn NJ, Appeah DK, Sims-Mourtada J. Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells [published online ahead of print, 2020 Jan 6]. Int J Radiat Biol. 2020;114. doi:10.1080/09553002.2020.1705423 [Pubmed][Article]

See the original post here:
Radiation, Inflammation and Triple-Negative Breast Cancer: A Study - OncoZine

Novel Potential Combination Therapy for Childhood Brain Tumors – Technology Networks

Medulloblastoma, the most common brain cancer in children, may arise from biological abnormalities in neural stem cells or neuronal precursors during embryonic development. Indeed, the clinical challenges of treatment resistance and tumor recurrence in patients with medulloblastomas appear to be related to the presence of cancer stem cells within medulloblastoma tumors.Brazilian researchers working in the Cancer and Neurobiology Laboratory at the Federal University of Rio Grande do Sul (Universidade Federal do Rio Grande do Sul, UFRGS), its university hospital (Hospital de Clnicas de Porto Alegre, HCPA), and the Children's Cancer Institute (Instituto do Cncer Infantil, ICI) in Porto Alegre, in collaboration with Canadian scientists working at the Hospital for Sick Children and the University of Toronto, analyzed gene expression in medulloblastoma tumors from patients. They demonstrated that all medulloblastoma tumor subtypes express two stem cell markers, namely the proto-oncogene protein BMI1 and the cell surface protein CD133. When DNA is in a tightly compacted chromatin state, the expression of genes that promote cell differentiation is reduced, thereby keeping cancer cells in a stem cell-like state. Accordingly, this team of researchers treated medulloblastoma cells with an epigenetic compound that inhibits histone deacetylase (HDAC) activity, leading to chromatin relaxation, and found that they could thereby reduce BMI1 and CD133 expression and hinder tumor cell viability.

Further analysis of tumor samples revealed that expression of these "stemness" markers appeared to be associated with activity of the mitogen-activated protein kinase (MAPK)/ERK intracellular signaling pathway. To test the importance of MAPK/ERK signaling in carcinogenesis, the researchers examined the effects of inhibiting MAPK/ERK in medulloblastoma cells. They found that MAPK/ERK inhibition reduced the cellular content of stemness markers and decreased cancer stem cell formation in culture. Importantly, these antitumor effects were potentiated when the tumor cells were exposed to HDAC inhibitors and MAPK/ERK inhibitors at the same time.

According to the lead author of the article reporting these findings, Dr. Mariane da Cunha Jaeger, "these findings suggest that combining HDAC and MAPK/ERK inhibitors may be a novel and effective approach to preventing medulloblastoma cell proliferation by altering the tumor stem cell phenotype".

Professor Rafael Roesler, senior author of the study, underscores that this work demonstrates how "integrating gene expression data from patient tumors with cell culture experiments can enable the identification of novel potential therapy combinations".

Commenting on the research team's research outlook in light of these promising findings, the ICI Research Director Dr. Andr T. Brunetto has said, "We are focusing on finding translational opportunities that can be explored in innovative clinical studies on childhood cancers".ReferenceJaegar et al. (2020) HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma. Journal of Molecular Neuroscience. DOI: https://doi.org/10.1007/s12031-020-01505-y

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Novel Potential Combination Therapy for Childhood Brain Tumors - Technology Networks